Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Depreciation & Amortization (CF) (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Depreciation & Amortization (CF) for 7 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 98.64% year-over-year to $1.5 million, compared with a TTM value of $4.2 million through Dec 2025, up 49.53%, and an annual FY2025 reading of $4.2 million, up 49.53% over the prior year.
  • Depreciation & Amortization (CF) was $1.5 million for Q4 2025 at Avidity Biosciences, up from $1.1 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.5 million in Q4 2025 and bottomed at $100000.0 in Q2 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $546300.0, with a median of $550000.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) dropped 14.53% in 2021, then surged 300.0% in 2022.
  • Year by year, Depreciation & Amortization (CF) stood at $200000.0 in 2021, then skyrocketed by 100.0% to $400000.0 in 2022, then soared by 50.0% to $600000.0 in 2023, then rose by 23.0% to $738000.0 in 2024, then surged by 98.64% to $1.5 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for RNA at $1.5 million in Q4 2025, $1.1 million in Q3 2025, and $800000.0 in Q2 2025.